PFM Health Sciences’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

PFM Health Sciences’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-318,948	Closed	-$11.9M	–	93
2023 Q1	$11.9M	Buy	+318,948	New	+$14.3M	0.52%	57
2022 Q1	–	Sell	-315,449	Closed	-$46.3M	–	79
2021 Q4	$46.3M	Buy	315,449 +14,904	+5%	+$2.31M	1.58%	27
2021 Q3	$53.2M	Buy	300,545 +13,499	+5%	+$2.17M	1.56%	26
2021 Q2	$46.4M	Sell	287,046 -22,734	-7%	-$3.65M	1.45%	26
2021 Q1	$53.1M	Buy	309,780 +100,774	+48%	+$20M	1.62%	21
2020 Q4	$45.9M	Sell	209,006 -40,062	-16%	-$8.66M	1.61%	22
2020 Q3	$41.4M	Buy	+249,068	New	+$34.1M	1.91%	17
2019 Q4	–	Sell	-431,123	Closed	-$33.6M	–	85
2019 Q3	$33.6M	Buy	+431,123	New	+$40.5M	0.99%	39
2019 Q2	–	Sell	-120,166	Closed	-$8.81M	–	105
2019 Q1	$8.81M	Buy	+120,166	New	+$8.17M	0.19%	81

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

PFM Health Sciences's MRTX Position: Q2 2023 in Review

PFM Health Sciences sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 318,948 shares — an estimated $11.9M sold.

PFM Health Sciences first reported a position in MRTX in Q1 2019 and held it in 9 quarters. The position peaked at $53.2M in Q3 2021. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

PFM Health Sciences reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
PFM Health Sciences sold 318,948 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $11.9M.
PFM Health Sciences first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 9 quarters.
PFM Health Sciences's Mirati Therapeutics, Inc. Common Stock position peaked at $53.2M in Q3 2021.
207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on PFM Health Sciences's 13F filing for Q2 2023, filed 14 Aug 2023.